 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || MK-4464 / Merck (MSD), Dragonfly Therap, Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed, Trial completion date, Trial primary completion date, Monotherapy, Metastases: Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) (clinicaltrials.gov) - Aug 13, 2024
P1, N=260, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Recruiting --> Active, not recruiting | Trial completion date: Oct 2027 --> Jul 2026 | Trial primary completion date: Oct 2027 --> Jul 2026
- ||| MK-4464 / Merck (MSD), Dragonfly Therap, Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Monotherapy, Metastases: Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) (clinicaltrials.gov) - Sep 30, 2022
P1, N=248, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Recruiting --> Active, not recruiting | Trial completion date: Oct 2027 --> Jul 2026 | Trial primary completion date: Oct 2027 --> Jul 2026 Not yet recruiting --> Recruiting
- ||| MK-4464 / Merck (MSD), Dragonfly Therap, Keytruda (pembrolizumab) / Merck (MSD)
New P1 trial, Monotherapy, Metastases: Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) (clinicaltrials.gov) - Aug 24, 2022
P1, N=260, Not yet recruiting, Sponsor: Merck Sharp & Dohme LLC